Results 111 to 120 of about 755,873 (344)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Prognostication of disease course and prediction of treatment response in multiple sclerosis is an unmet need. We compared the performance of serum neurofilament light chain Z scores (age‐ and BMI‐adjusted) with absolute concentrations for the prediction of response to disease‐modifying therapy.
Maximilian Einsiedler +43 more
wiley +1 more source
Relapsing-remitting multiple sclerosis: advances in disease-modifying therapies [PDF]
, 2015 Multiple sclerosis is a demyelinating disease affecting the central nervous system. It is the most prevalent disabling neurological condition among young adults, with onset typically between 20 and 40 years of age. Infiltrating immune cells and microglia
Kay, Kathleen Alexandra
core +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To investigate the overall use of prescription medications among individuals with multiple sclerosis compared to the general population, with a focus on treatments beyond disease‐modifying therapies. Methods We conducted a nationwide, registry‐based study in Denmark.
Josefine Windfeld‐Mathiasen +4 more
wiley +1 more source
Frontiers in Immunology, 2018 Background: The majority of persons diagnosed with multiple sclerosis (MS) experience their first MS symptoms in the reproductive age. Teriflunomide (TFL, Aubagio), was first released in Denmark for relapsing-remitting MS in December 2013.
Johanna Balslev Andersen +4 more
doaj +1 more source
The rs10191329 Risk Allele Is Associated With Pronounced Retinal Layer Atrophy in Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To investigate whether the rs10191329 risk allele in the DYSF–ZNF638 locus, which is implicated in central nervous system resilience rather than immune‐mediated pathology, is associated with retinal layer thinning, a biomarker of neuroaxonal damage in relapsing multiple sclerosis (RMS). Methods From a prospective observational study,
Gabriel Bsteh +22 more
wiley +1 more source
Pyoderma gangrenosum in a patient with multiple sclerosis under natalizumab treatment: a case report
BMC NeurologyBackground Pyoderma Gangrenosum (PG) is often considered an immune-mediated disease. Up to 50% of PG cases - a rare, non-infectious inflammatory skin disease characterized by painful necrotic ulcers -are associated with underlying systemic diseases like ...
Kosar Kohandel +4 more
doaj +1 more source
Evaluating Cognitive-Motor Interference in Multiple Sclerosis: A Technology-Based Approach
BioengineeringBackground: People with multiple sclerosis (PwMS) frequently present both cognitive and motor impairments, so it is reasonable to assume they may have difficulties in executing dual-tasks (DT). The aim of the present study is to identify novel technology-
Jessica Podda +3 more
doaj +1 more source
Group sequential designs for negative binomial outcomes
, 2018 Count data and recurrent events in clinical trials, such as the number of lesions in magnetic resonance imaging in multiple sclerosis, the number of relapses in multiple sclerosis, the number of hospitalizations in heart failure, and the number of ...
Friede, Tim +3 more
core +1 more source
MULTIPLE DEGENERATIVE SOFTENING VERSUS MULTIPLE SCLEROSIS [PDF]
, 1922 George B. Hassin
openalex +1 more source